%0 Journal Article
%A Albers, Peter
%A Krilaviciute, Agne
%A Seibold, Petra
%A de Vrieze, Maxime
%A Lakes, Jale
%A Kuczyk, Markus A
%A Harke, Nina N
%A Debus, Jürgen
%A Grott, Christoph A
%A Gschwend, Jürgen E
%A Herkommer, Kathleen
%A Soehne, Victoria A
%A Benner, Axel
%A Kristiansen, Glen
%A Hadaschik, Boris
%A Arsov, Christian
%A Antoch, Gerald
%A Schimmöller, Lars
%A Giesel, Frederik L
%A Makowski, Marcus R
%A Wacker, Frank
%A Schlemmer, Heinz-Peter
%A Kaaks, Rudolf
%A Becker, Nikolaus
%T Do We Need Early Detection of Grade Group 2 Prostate Cancer in a Screening Program for Young Men? Results from the PROBASE Screening Trial.
%J European urology oncology
%V nn
%@ 2588-9311
%C Amsterdam
%I Elsevier
%M DKFZ-2025-01430
%P nn
%D 2025
%Z #EA:C130#LA:C130# / epub
%X In general, low-risk and favorable intermediate-risk prostate cancers (PCs; International Society of Urological Pathology grade group [GG] 1 and GG 2) are slow-growing cancers with low metastatic potential. Active surveillance is recommended for GG 1 PC and can be recommended for GG 2 PC in the absence of adverse pathological parameters. Therefore, the question arises as to when low-grade PC should be detected in a screening setting. We conducted an analysis of the group with intermediate prostate-specific antigen (PSA) risk (1.5-2.99 ng/ml) from the PROBASE screening trial for young men (starting age 45 yr) and evaluated 159 biopsies performed for confirmed PSA ≥3 ng/ml in the first two biennial screening rounds. Of these biopsies, 37
%K Grade group (Other)
%K Intermediate risk (Other)
%K International Society of Urological Pathology (Other)
%K Prostate cancer (Other)
%K Screening (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40640052
%R 10.1016/j.euo.2025.06.007
%U https://inrepo02.dkfz.de/record/302890